A recent study suggests that certain cancer progression proteins and metastasis are stored as amyloid bodies in dormant cancer cells.
Once the amyloid bodies disaggregate, the cancer cells become active again.
Amyloid bodies are known to play a role in the development of neurological diseases such as Alzheimer's and Parkinson's disease but their contributions to the progression of cancer have been largely unknown.
This discovery points to a new avenue for the treatment of various types of cancers by applying knowledge gained from neuroscience to tumor biology.
The author of the study Stephen Lee said, "The amyloid state of protein organization is typically associated with debilitating human neuropathies and rarely observed in physiology,"
Adding, "Yet, we found that a large number of proteins are stored as amyloid bodies in cancer cells that are dormant. The heat shock chaperone pathway can disaggregate the amyloid bodies and turn the dormant cancer cells into active, progressing cancer cells."
The team found that ribosomal intergenic non-coding RNA regulates the process of amyloid formation in cancer cells, making it a target for drug discovery and development.
"If we can stop the amyloid bodies from disaggregating in cancer cells, the hope is that they will remain dormant indefinitely. In addition, we may also be able to turn active cancer cells into dormant ones by encouraging them to store the proteins as amyloid bodies," Lee said.
Amyloidogenesis enables cells to remain viable during prolonged periods of extracellular stress, highlighting the non-toxic and protective nature of the process, not just in cancer cells.
"Following this approach, we wouldn't necessarily rid the body of cancer cells, but we would keep them inactive - shut off, if you will- and not allow them to become active againI am optimistic this could become a novel way of treating cancer. There are already drugs on the market, and others are being studied, that target the ribosomal intergenic noncoding RNA as well as the heat shock chaperone pathway," he said.
The findings were published in the journal Developmental Cell today.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
